MIPI Alliance Releases MIPI CCS, a New Specification that Streamlines Integration of Image Sensors in Mobile Devices
The MIPI® Alliance, an international organization that develops interface specifications for mobile and mobile-influenced industries, today released a new specification that provides a standardized way to integrate image sensors in mobile-connected devices.
The new specification, MIPI Camera Command Set v1.0 (MIPI CCS v1.0), defines a standard set of functionalities for implementing and controlling image sensors. The specification is offered for use with MIPI Camera Serial Interface 2 v2.0 (MIPI CSI-2 v2.0) and is now available for download. In an effort to help standardize use of MIPI CSI-2, MIPI Alliance membership is not required to access the specification.
MIPI CSI-2 is the industry’s most widely used hardware interface for deploying camera and imaging components in mobile devices. The introduction of MIPI CCS to MIPI CSI-2 further increases interoperability, and reduces integration and costs for complex imaging and vision systems.
“MIPI Alliance is building on its success in the mobile camera and imaging ecosystem with MIPI CCS, a new specification that will enhance the market-enabling conveniences MIPI CSI-2 already provides,” said Joel Huloux, chairman of MIPI Alliance. “The availability of MIPI CCS will help image sensor vendors promote greater adoption of their technologies and it will help developers accelerate time-to-market with innovative designs targeting the mobile industry, connected cars, the Internet of Things, AR/VR and other areas.”
From startups to global organizations, companies are integrating image sensor components into their designs for specialized and mass-market products. To date, image sensor integration has required device-specific software to enable basic operations. As imaging applications have become more sophisticated and manufacturers have begun deploying multiple image sensors in their products, implementation has become more complex and time consuming.
MIPI CCS alleviates these challenges by making it possible to craft a common software driver to configure the basic functionalities of any off-the-shelf image sensor that is compliant with MIPI CCS and MIPI CSI-2 v2.0. The new specification provides a complete command set that can be used to integrate basic image sensor features such as resolution, frame rate and exposure time, as well as advanced features like phase detection auto focus (PDAF), single frame HDR or fast bracketing.
“The overall advantage of MIPI CCS is that it will enable rapid integration of basic camera functionalities in plug-and-play fashion without requiring any device-specific drivers, which has been a significant pain point for developers,” said Mikko Muukki, technical lead for MIPI CCS. “MIPI CCS will also give developers flexibility to customize their implementations for more advanced camera and imaging systems.”
MIPI CCS v1.0 was developed for use with MIPI CSI-2 v2.0 and, as such, is backward compatible with earlier versions of the MIPI CSI-2 interface. It is implemented on either of two physical layers from MIPI Alliance: MIPI C-PHY or MIPI D-PHY.
Join the MIPI CCS v1.0 Webinar
Developers are invited to attend a webinar “Introduction to MIPI Camera Command Set v1.0” on 10 January at 11 a.m. EST, 8 a.m. PST. For information and registration, please go to: http://bit.ly/2jMIp2g.
To discover more about MIPI Alliance and to connect with its social networks, follow its Twitter page, join its LinkedIn group and like its Facebook page. To join MIPI Alliance, use the Join MIPI link on the organization’s site.
About MIPI Alliance
MIPI Alliance (MIPI) develops interface specifications for mobile and mobile-influenced industries. There is at least one MIPI specification in every smartphone manufactured today. Founded in 2003, the organization has 300 member companies worldwide and 13 active working groups delivering specifications within the mobile ecosystem. Members of the organization include handset manufacturers, device OEMs, software providers, semiconductor companies, application processor developers, IP tool providers, test and test equipment companies, as well as camera, tablet and laptop manufacturers. For more information, please visit www.mipi.org.
MIPI® is a registered trademark owned by MIPI Alliance. MIPI CSI-2SM v2.0, MIPI CCS SM, MIPI C-PHYSM and MIPI D-PHYSM are service marks of the MIPI Alliance.
Interprose for MIPI Alliance
Lisa McCausland, +1 303-888-2137
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Heidelberg Engineering Announces the CE-Marking of ANTERION21.9.2018 16:41 | Pressemelding
Heidelberg Engineering, the leader in diagnostic imaging known for the internationally-acclaimed SPECTRALIS ® retina and glaucoma platform, announces the CE-marking of ANTERION ® – an innovative platform designed to transform anterior segment diagnostics and workflow. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005442/en/ The new Heidelberg Engineering ANTERION® provides the most important anterior segment examinations and measurements in one modular, upgradeable platform. (Graphic: Business Wire) The new ANTERION provides the most important anterior segment examinations and measurements in one modular, upgradeable platform. It is a single, workflow-efficient solution that brings together corneal topography and tomography, anterior segment metrics, axial length measurement and IOL calculation to transform the day-to-day routine of busy practices and clinics. Heidelberg Engineering has leveraged its core OCT technolo
Florian Winterstein Becomes New CEO of Jedox21.9.2018 15:46 | Pressemelding
The supervisory board of Jedox AG, a leading vendor of business intelligence and enterprise planning software, has appointed Florian Winterstein as Chief Executive Officer (CEO) effective October 2, 2018. This nomination will support Jedox’s international growth and a new development phase initiated by its latest fund raising in April 2018 with Iris Capital, eCAPITAL entrepreneurial Partners AG and Wecken & Cie. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005416/en/ Florian Winterstein (Photo: Business Wire) With 25 years of experience in strategy consulting and leadership in software and service organizations, Winterstein brings to the company a valuable combination of expertise in cloud solutions, business development, and value creation for customers and partners. As former Chief Strategy Officer of BravoSolution, he positioned the software-as-a-service company as trendsetting digitalization partner, extending it
Takeda Receives Positive CHMP Opinion Recommending ALUNBRIG® (brigatinib) for the Treatment of ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib21.9.2018 13:30 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the full approval of ALUNBRIG® (brigatinib) as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib. ALUNBRIG is a tyrosine kinase inhibitor (TKI) designed to target and inhibit the ALK mutation in NSCLC. Approximately three to five percent of NSCLC patients globally have the ALK mutation. If the CHMP opinion is affirmed, and the European Commission approves ALUNBRIG, it will become the only ALK inhibitor available in the European Union as a one tablet per day dose that can be taken with or without food. The randomized, global Phase 2 ALTA trial was designed to investigate the efficacy and safety of ALUNBRIG in patients with locally advanced or metastatic ALK+
Asda Selects HCL Technologies to Help Drive IT Transformation21.9.2018 12:16 | Pressemelding
HCL Technologies (HCL), a leading global technology company, today announced that it has been selected to help drive IT transformation at the UK’s third-largest grocery retailer, Asda. The three-year application services contract will see HCL transform Asda’s IT Application Services with a new DevOps delivery model to drive data and analytics and support back-office applications through the full lifecycle of development, testing and support. HCL will also build a central data management platform to enable Asda to improve its insight and analytics capabilities. Asda operates more than 600 stores across the UK, employing over 135,000 people. Asda wanted to adopt a more agile approach towards application development and testing. This would allow the company to respond faster to business requirements and reduce time to market, while driving better user experience and satisfaction. HCL was selected due to its extensive expertise in successfully delivering similar large scale IT transformati
Ipsen Receives Positive CHMP Opinion for Cabometyx® (Cabozantinib) for the Second-line Treatment of Patients with Hepatocellular Carcinoma (HCC)21.9.2018 05:30 | Pressemelding
Regulatory News: Ipsen (Euronext:IPN; ADR:IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), provided a positive opinion for Cabometyx® (cabozantinib) as a monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have been previously treated with sorafenib. The CHMP positive opinion will now be reviewed by the European Commission (EC), which has the authority to approve medicines for the European Union (EU). Alexandre Lebeaut, MD, Executive Vice President, R&D and Chief Scientific Officer, Ipsen, said: “The global burden of liver cancer is increasing and despite the recent introduction of new agents, it remains the second leading cause of cancer mortality worldwide. Following today’s positive CHMP opinion and if approved by the European Commission, Cabometyx ® as monotherapy will give patients with HCC a much-needed new oral therapeutic option.” Dr Lorenza Rimassa,
Quanergy Selected as Exclusive LiDAR Partner for VRCO21.9.2018 05:00 | Pressemelding
Quanergy Systems, Inc., a global leader in the design and development of solid state LiDAR sensors and smart sensing solutions, and VRCO, designer and manufacturer of the luxury high-end e-VTOL (electric Vertical Take-Off and Landing) craft, the NeoXcraft XP2, today announced that VRCO will exclusively use Quanergy’s S3 solid state LiDAR sensors in the testing and market release versions of the aircraft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180920006036/en/ VRCO NeoXcraft XP2 with Quanergy S3 LiDAR Sensor (Graphic: Business Wire) The NeoXcraft XP2, which VRCO and the University of Derby unveiled in late 2017 and intend to launch in 2020, is a two-passenger e-VTOL high-speed land, air, and water capable craft. The craft can scan and memorize take-off locations and store the data for use on the next approach to the same location. Quanergy’s innovative S3 solid state LiDAR sensor will be used for downward and forward